Company intelligence / Profile preview

Belenos Biosciences

New York, New York, United Statesprofiles.biocentury.com ↗

Ownership: Private
Development stage: Phase 1

Overview

The company is operating in stealth mode and has recently licensed two bispecific antibodies (CM512 and CM536) from Keymed Biosciences for development and commercialization globally, excluding the Greater China region[5].

Modalities: Bispecific antibodies
Industry: Biotech

Drug pipeline

1 asset

BEL536

Unknown

Partnerships

Keymed Biosciences (China)

Beyond the preview

Go deeper on Belenos Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Belenos Biosciences.

Explore the full profile